论文部分内容阅读
目的观察雌激素受体(ER)、孕激素受体(PR)、原癌基因Her-2(C-erB-2)与肺腺癌骨转移的关系,并对肺腺癌患者出现骨转移的时间及生存期进行多因素相关分析。方法 96例肺腺癌患者入组本研究,通过免疫组化检测术后标本上述受体的表达。结果 ER、PR和C-erB-2的表达在骨转移及非骨转移两组间的差异均无统计学意义(P分别为0.34、0.60、0.26),但骨转移组上述受体一旦表达,表达程度均较高,多为++或+++。T分期、N分期越低,出现骨转移的时间及总生存期(OS)越长。ER和C-erB-2阳性和阴性表达组之间出现骨转移的时间及OS的差异均有统计学意义(P<0.05)。结论 ER、PR、C-erB-2与肺腺癌是否出现骨转移无相关性;ER、C-erB-2与肺腺癌出现骨转移的时间及预后密切相关。
Objective To observe the relationship between estrogen receptor (ER), progesterone receptor (PR), proto-oncogene Her-2 (C-erB-2) and bone metastasis of lung adenocarcinoma. Time and survival of multi-factor correlation analysis. Methods Ninety-six patients with lung adenocarcinoma were enrolled in this study. The expressions of these receptors were detected by immunohistochemistry. Results There was no significant difference in the expression of ER, PR and C-erB-2 between the two groups (P 0.34, 0.60, 0.26 respectively). However, once the above receptors were expressed in bone metastasis group, The expression level is higher, mostly ++ or +++. T staging, the lower the N staging, the longer bone metastasis and overall survival (OS). The time of bone metastasis and the difference of OS between ER and C-erB-2 positive and negative expression groups were statistically significant (P <0.05). Conclusions ER, PR, C-erB-2 have no correlation with bone metastasis of lung adenocarcinoma. ER and C-erB-2 are closely related to the time and prognosis of bone metastasis of lung adenocarcinoma.